Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders frequently develop in patients with acquired immunodeficiency syndrome (AIDS). The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective. However, we report about two AIDS patients with EBV-associated lymphoproliferative disorders not responding to a standard chemotherapy, who achieved complete tumour regression after virustatic therapy with foscarnet.

Spontaneous Regression of Diffuse Large B-Cell Lymphoma Harbouring Epstein-Barr Virus: A Case Report and Review of the Literature

“…Indeed, many cases in table 1 indicated that the trigger for reduction in the size of LNs was apparently biopsy alone, except in 2 cases developing measles shortly after diagnostic biopsy 6 and our case. Schneider et al reported regression of EBV-associated LPDs in 2 AIDS patients after therapy with an inhibitor of viral DNA polymerases 24 . Our patient might have had unstable immunocompetence due to his advanced age of about 90.…”

Prevention and Treatment of Epstein—Barr Virus Associated Lymphoproliferative Disorders in Recipients of Bone Marrow and Solid Organ Transplants

“…Nevertheless, as toxicity of acyclovir therapy is low, treatment with acyclovir is often instituted when EBV-LPD has been diagnosed. Two case reports described the achievement of CR of EBV disease after treatment with ganciclovir or foscarnet (Gruhn et al, 1999;Schneider et al, 2000). Little information is available on the effectiveness of newer antiviral agents regarding prevention or treatment of EBV-LPD.…”

Identification of early antigen BZLF1/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post‐transplant lymphoproliferative disease

“…After a 3 week course with foscarnet, the patient achieved a CR lasting 20 months (at the time of reporting). Also, Schneider et al (2000) reported two further HIV‐infected patients with EBV‐associated lymphoproliferations, who achieved complete remissions after treatment with foscarnet.…”